Citric Acid

Citric Acid

SCHEMBL2227446

O=C([O-])CC(O)(CC(=O)O)C(=O)[O-].[Ag+].[Ag+]

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.73
ALDH1A1 P00352 1/20 0.50
HMGCR P04035 1/20 0.39
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
ADRA1A P35348 1/20 0.39
ACLY P53396 3/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
CPT2 P23786 1/20 0.31
SLC13A5 Q86YT5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citric Acid SCHEMBL2227442 0.98 CA4 (0.70) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL5471630 0.98 CA4 (0.76) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL9319655 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL21569398 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL2227453 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL1684057 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL1301477 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL21569387 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL18263181 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R
Citric Acid SCHEMBL475574 0.95 CA4 (0.73) CA4ALDH1A1HMGCRCHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335353-B Composition containing hydrogen citrate and dipsilver, process for producing the same, and antibacterial agent or antiviral agent using the same and process for producing the same 佐佐木化学工业株式会社 2023-06-09 CN claimed
US-20230089450-A1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL INDUSTRY CO., LTD. (JP) 2023-03-23 US claimed
US-11528930-B2 Short-term wash treatment of produce SMARTWASH SOLUTIONS, LLC (US) 2022-12-20 US claimed
US-20210244066-A1 SHORT-TERM WASH TREATMENT OF PRODUCE SMARTWASH SOLUTIONS, LLC 2021-08-12 US claimed
US-20130171224-A1 TREATMENT OF BIOFILMS ADVANCED MEDICAL SOLUTIONS LIMITED (GB) 2013-07-04 US claimed
WO-2011089379-A2 TREATMENT OF BIOFILMS ADVANCED MEDICAL SOLUTIONS LIMITED (GB) 2011-07-28 WO claimed
US-12604898-B2 Disilver hydrogen citrate-containing composition, method for producing same, antibacterial agent or antiviral agent using same, and method for producing same SASAKI CHEMICAL INDUSTRY CO., LTD. (JP) 2026-04-21 US disclosed
EP-4169899-B1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL IND CO LTD (JP) 2026-04-08 EP disclosed
EP-4169899-B1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL IND CO LTD (JP) 2026-04-08 EP disclosed
EP-4169899-C0 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL IND CO LTD (JP) 2026-04-08 EP disclosed
CN-120787966-A Silver-containing disinfection composition and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2025-10-17 CN disclosed
EP-4169899-A4 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME Sasaki Chemical Industry Co., Ltd. (JP) 2024-06-26 EP disclosed
CN-115335353-B Composition containing hydrogen citrate and dipsilver, process for producing the same, and antibacterial agent or antiviral agent using the same and process for producing the same 佐佐木化学工业株式会社 2023-06-09 CN disclosed
EP-4169899-A1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME Sasaki Chemical Industry Co., Ltd. (JP) 2023-04-26 EP disclosed
US-20230089450-A1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL INDUSTRY CO., LTD. (JP) 2023-03-23 US disclosed
US-20230089450-A1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME SASAKI CHEMICAL INDUSTRY CO., LTD. (JP) 2023-03-23 US disclosed
CN-115335353-A Hydrogen-bis-silver citrate-containing composition and method for producing same, and antibacterial agent or antiviral agent using same and method for producing same 佐佐木化学工业株式会社 2022-11-11 CN disclosed
JP-2022164635-A COMPOSITION CONTAINING DISILVER HYDROGEN CITRATE AND ITS MANUFACTURING METHOD, AS WELL AS ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING THE SAME AND ITS MANUFACTURING METHOD 佐々木化学工業株式会社 2022-10-27 JP disclosed
US-20130171224-A1 TREATMENT OF BIOFILMS ADVANCED MEDICAL SOLUTIONS LIMITED (GB) 2013-07-04 US disclosed
WO-2011089379-A2 TREATMENT OF BIOFILMS ADVANCED MEDICAL SOLUTIONS LIMITED (GB) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12604898-B2 Disilver hydrogen citrate-containing composition, method for producing same, antibacterial agent or antiviral agent using same, and method for producing same ACLY, CS, SAMHD1 CA4 391/4885ALDH1A1 1979/4885HMGCR 925/4885
US-20230089450-A1 DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAME CS, ACLY, DAD1 CA4 128/4885ALDH1A1 2677/4885HMGCR 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.